In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Effect of cardiovascular comorbidities on the mortality risk associated with serum potassium

Session Poster session 1 Saturday 08:30 -17:30

Speaker Bertram Pitt

Congress : Heart Failure 2015

  • Topic : e-cardiology / digital health, public health, health economics, research methodology
  • Sub-topic : Research Methodology
  • Session type : Poster Session
  • FP Number : P458

Authors : B Pitt (Ann Arbor,US), AJ Collins (Minneapolis,US), NL Reaven (La Cañada Flintridge,US), SA Funk (La Cañada Flintridge,US), GL Bakris (Chicago,US), DA Bushinsky (Rochester,US)

Authors:
B Pitt1 , AJ Collins2 , NL Reaven3 , SA Funk3 , GL Bakris4 , DA Bushinsky5 , 1University of Michigan School of Medicine - Ann Arbor - United States of America , 2University of Minnesota - Minneapolis - United States of America , 3Strategic Health Resources - La Cañada Flintridge - United States of America , 4University of Chicago Medicine - Chicago - United States of America , 5University of Rochester - Rochester - United States of America ,

Citation:
European Journal of Heart Failure Abstracts Supplement ( 2015 ) 17 ( Supplement 1 ), 107

Purpose: Hypo- and hyperkalemia are associated with an increased mortality risk. Serum potassium (K+) levels associated with these risks and relationships to comorbidity, however, are not well defined. We evaluated the odds of death in patients with and without comorbid conditions, stratified by K+ level.

Methods: De-identified medical records (2007-2012) from a large US population aged ≥5 years with 2 or more K+ readings were evaluated. Patients aged 45-64 years with comorbidities of CKD stages 3-5, heart failure, diabetes, hypertension, and cardiovascular disease (n = 231,070) were identified by ICD-9 codes and biochemical data, excluding those with acute kidney injury or end stage renal disease, and compared with controls without these conditions (n = 146,645). A separate analysis of patients aged ≥65 years was conducted. Index K+ value was defined as the last reported value prior to a pre-determined cut-off date. Mortality was evaluated through hospital discharge records and Social Security registry information.

Results: Patients with cardiorenal comorbidities aged 45-64 years and index K+ levels <4.1 mEq/L and >4.6 mEq/L had a significant increase in mortality (Figure). This finding was also observed in patients aged ≥65 years. The general pattern remained after adjustments for demographic characteristics (sex, race) and comorbidities associated with the propensity to develop hypo- and hyperkalemia.

Conclusions: Our results confirm that patients with hypo- or hyperkalemia are at greater risk for mortality than those with normal K+, and that mortality risk is significantly higher in patients with cardiorenal comorbidities and is independent of demographic characteristics. The increased mortality in patients with comorbidities occurs even at K+ levels within the usual normal laboratory range.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are